Our findings of ERCC2 mutations in 3% of epithelioid sarcoma and 6.45% of perivascular epithelioid cell tumors, the trend for increased HRD scores among ERCC2-mutated sarcomas, and the trend for shorter overall survival among patients with ERCC2 mutation support the further investigation of the role of ERCC2 in sarcoma pathogenesis and treatment. Here, ERCC2 is linked to epithelioid sarcoma.